

Pere Barba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993933/publications.pdf>

Version: 2024-02-01

118
papers

3,175
citations

159585

30
h-index

182427

51
g-index

119
all docs

119
docs citations

119
times ranked

4420
citing authors

#	ARTICLE	IF	CITATIONS
1	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	1.3	8
2	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Advances</i> , 2022, 6, 774-784.	5.2	42
3	Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy. <i>Hematological Oncology</i> , 2022, , .	1.7	2
4	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	27.0	243
5	Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment. <i>Medicina Clínica (English Edition)</i> , 2022, , .	0.2	0
6	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 3606-3610.	5.2	35
7	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
8	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. <i>American Journal of Transplantation</i> , 2021, 21, 258-271.	4.7	11
9	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	1.4	48
10	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. <i>Infection</i> , 2021, 49, 215-231.	4.7	63
11	Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 114-125.	2.2	2
12	Combining the disease risk index and hematopoietic cell transplant comorbidity index provides a comprehensive prognostic model for CD34 selected allogeneic transplantation. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, .	0.9	0
13	Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. <i>Bone Marrow Transplantation</i> , 2021, 56, 1784-1793.	2.4	5
14	Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. <i>Leukemia and Lymphoma</i> , 2021, 62, 2288-2291.	1.3	1
15	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 3214-3223.	2.8	73
16	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. <i>Annals of Hematology</i> , 2021, 100, 2303-2310.	1.8	32
17	Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. <i>Hematological Oncology</i> , 2021, 39, 529-538.	1.7	3
18	Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. <i>British Journal of Haematology</i> , 2021, , .	2.5	2

#	ARTICLE	IF	CITATIONS
19	Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia Research</i> , 2021, 109, 106612.	0.8	11
20	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	7.2	72
21	Real-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study. <i>Blood</i> , 2021, 138, 3850-3850.	1.4	0
22	Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 2827-2827.	1.4	2
23	A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge™ platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2021, 138, 740-740.	1.4	21
24	Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. <i>Blood</i> , 2021, 138, LBA-6-LBA-6.	1.4	9
25	Terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) en pacientes con linfoma de célula B agresivo. Perspectiva actual tras una década de tratamiento. <i>Medicina Clínica</i> , 2021, .	0.6	0
26	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	2.5	31
27	Feasibility of thiotepea addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	1.3	1
28	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, e294-e297.	3.5	29
29	Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. <i>Leukemia</i> , 2020, 34, 3420-3425.	7.2	22
30	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
31	Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 271.	4.8	9
32	A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , 2020, 9, 2317-2329.	2.8	13
33	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e513-e522.	0.4	5
34	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-21.	1.4	4
35	Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. <i>Blood</i> , 2020, 136, 27-29.	1.4	0
36	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	2.8	6

#	ARTICLE	IF	CITATIONS
37	Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 28-34.	0.2	1
38	Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. <i>Cancer</i> , 2019, 125, 2810-2817.	4.1	13
39	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	2.5	6
40	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
41	Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report. <i>Bone Marrow Transplantation</i> , 2019, 54, 772-774.	2.4	4
42	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86.	2.2	14
43	Allogeneic Stem Cell Transplantation with CD34+ Cell Selection. <i>Clinical Hematology International</i> , 2019, 1, 154-160.	1.7	5
44	El trasplante alogénico de progenitores hematopoyéticos en la era de las nuevas terapias en la leucemia linfoblástica aguda. <i>Medicina Clínica</i> , 2019, 153, 28-34.	0.6	2
45	Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2018, 20, e12897.	1.7	11
46	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 964-972.	2.0	19
47	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2018, 68, 79-84.	0.8	9
48	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 146-154.	1.3	17
49	Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 101, 407-414.	2.2	7
50	Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2075-2082.	2.9	6
51	Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1634-1643.	1.3	13
52	Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab. <i>Blood</i> , 2018, 132, 3402-3402.	1.4	1
53	Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Leukemia and Lymphoma</i> , 2017, 58, 145-152.	1.3	7
54	Asparinasas en el tratamiento de la leucemia linfoblástica aguda. <i>Medicina Clínica</i> , 2017, 148, 225-231.	0.6	3

#	ARTICLE	IF	CITATIONS
55	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1177-1185.	2.0	22
56	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. <i>Annals of Hematology</i> , 2017, 96, 1069-1075.	1.8	21
57	Do Patients and Physicians Agree When They Assess Quality of Life?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1005-1010.	2.0	12
58	Ex Vivo CD34+â€œSelected T Cellâ€œDepleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 452-458.	2.0	35
59	Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. <i>Experimental Hematology</i> , 2017, 48, 1-11.	0.4	54
60	Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. <i>Lancet Haematology</i> , 2017, 4, e573-e583.	4.6	161
61	Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. <i>Bone Marrow Transplantation</i> , 2017, 52, 107-113.	2.4	45
62	Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 491-497.	2.0	37
63	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 67-74.	2.0	24
64	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	5.2	6
65	Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1463-1468.	1.4	18
66	Cord Blood Units with High CD3 + Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cellâ€œDepleted Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1073-1079.	2.0	11
67	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	3.5	118
68	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. <i>Leukemia Research</i> , 2016, 41, 12-20.	0.8	41
69	The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with doseâ€œintensive chemotherapy including rituximab. <i>British Journal of Haematology</i> , 2016, 172, 428-438.	2.5	20
70	Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 564-570.	2.0	8
71	Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 120-124.	1.3	16
72	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of postâ€œtransplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016, 96, 128-135.	2.2	19

#	ARTICLE	IF	CITATIONS
73	Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. <i>Leukemia and Lymphoma</i> , 2016, 57, 86-91.	1.3	14
74	Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. <i>Cancer</i> , 2015, 121, 3809-3817.	4.1	43
75	Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34 ⁺ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). <i>Transplant Infectious Disease</i> , 2015, 17, 221-233.	1.7	10
76	Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. <i>Bone Marrow Transplantation</i> , 2015, 50, 579-584.	2.4	49
77	GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 121-126.	2.4	8
78	Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34 ⁺ cell levels and preemptive intervention vs remobilization. <i>Bone Marrow Transplantation</i> , 2015, 50, 34-39.	2.4	36
79	Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 682-687.	2.0	7
80	Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2015, 94, 911-918.	1.8	49
81	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. <i>Brain</i> , 2015, 138, 2847-2858.	7.6	128
82	Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1371-1374.	2.4	4
83	Post-Thaw Viable CD45 ⁺ Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2167-2172.	2.0	17
84	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2812-2818.	1.3	5
85	Serum Galactomannan Versus a Combination of Galactomannan and Polymerase Chain Reaction-Based Aspergillus DNA Detection for Early Therapy of Invasive Aspergillosis in High-Risk Hematological Patients: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 405-414.	5.8	133
86	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2015, 126, 1333-1333.	1.4	9
87	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	3.0	16
88	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 378-384.	3.5	16
89	Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. <i>Annals of Hematology</i> , 2014, 93, 299-307.	1.8	38
90	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Cancer</i> , 2014, 120, 3958-3964.	4.1	24

#	ARTICLE	IF	CITATIONS
91	Treatment of High-Risk Philadelphia Chromosome ⁺ Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1595-1604.	1.6	227
92	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 66-72.	2.0	41
93	The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014, 99, e55-e57.	3.5	51
94	Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome. <i>Blood</i> , 2014, 124, 1165-1165.	1.4	0
95	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. <i>Blood</i> , 2014, 124, 3798-3798.	1.4	0
96	Impact of Hyperferritinemia on the Outcome of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 597-601.	2.0	6
97	Dose ⁺ intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status. <i>Cancer</i> , 2013, 119, 1660-1668.	4.1	63
98	The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus. <i>Blood</i> , 2013, 122, 4529-4529.	1.4	0
99	Therapy Related Acute Lymphoblastic Leukemia: Pethema Experience. <i>Blood</i> , 2013, 122, 4994-4994.	1.4	1
100	Intensive Immunochemotherapy In Patients With B-Cell Lymphoma, Unclassifiable (B-UCL), With Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Burkitt Lymphoma (BL): A Comparison With BL Patients Treated With The Same Protocol In The Pethema-Burkimab-04 Trial. <i>Blood</i> , 2013, 122, 1793-1793.	1.4	1
101	Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2012, 47, 1343-1349.	2.4	13
102	Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. <i>American Journal of Hematology</i> , 2012, 87, 631-634.	4.1	29
103	Degree of mucositis and duration of neutropenia are the major risk factors for early post ⁺ transplant febrile neutropenia and severe bacterial infections after reduced ⁺ intensity conditioning. <i>European Journal of Haematology</i> , 2012, 88, 46-51.	2.2	20
104	Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. <i>American Journal of Hematology</i> , 2012, 87, 9-14.	4.1	23
105	Prognostic Value of Complex Karyotype and Monosomal Karyotype in Patients with Adult Acute Lymphoblastic Leukemia Treated with Risk-Adapted Protocols. <i>Blood</i> , 2012, 120, 4785-4785.	1.4	0
106	The Combination of the EBMT Score and the HCT-CI Is Not Better Than the HCT-CI Alone in the Prediction of NRM and OS in Patients Undergoing Allogeneic Hematopoietic Transplantation with Reduced-Toxicity Conditioning. <i>Blood</i> , 2012, 120, 1925-1925.	1.4	0
107	Pretransplantation Liver Function Impacts on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Study of 455 Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1653-1661.	2.0	17
108	Invasive Aspergillosis Complicating Pandemic Influenza A (H1N1) Infection in Severely Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2011, 53, e16-e19.	5.8	91

#	ARTICLE	IF	CITATIONS
109	Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. <i>Bone Marrow Transplantation</i> , 2010, 45, 534-542.	2.4	32
110	MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. <i>Bone Marrow Transplantation</i> , 2010, 45, 1449-1456.	2.4	43
111	Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 413-420.	2.0	67
112	Hepatic Toxicity After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation: Incidence, Characteristics and Risk Factors In a Cohort of 452 Patients.. <i>Blood</i> , 2010, 116, 3495-3495.	1.4	0
113	Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 21-29.	2.0	53
114	Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1439-1446.	2.0	79
115	Antithrombin Cambridge II mutation as a risk factor to develop cerebral venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 443-444.	3.4	2
116	Validation of Comorbidity Indexes in Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation. the Hematopoietic Cell Transplantation Comorbidity Index Is the Best Predictor of NRM and Survival.. <i>Blood</i> , 2008, 112, 3277-3277.	1.4	2
117	Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor.. <i>Blood</i> , 2008, 112, 2229-2229.	1.4	0
118	Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	13